DCOY — Decoy Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-Albemarle, Lowe's, nLIGHT
U.S. STOCKS ON THE MOVE-Cardinal Health, Decoy Therapeutic
Decoy Therapeutics rises as Gates Foundation backs antiviral drug access
Brief: Decoy Therapeutics Reaches Global Access Commitment Agreement To Focus On Development Of A Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform
Brief: Salarius Pharmaceuticals Changes Name To Decoy Therapeutics
Brief: Salarius Pharmaceuticals Announces Name And Ticker Change To Decoy Therapeutics
Brief: Salarius Pharmaceuticals To Collaborate With Texas Biomedical Research Institute On Avian Flu Study
Brief: Salarius Pharmaceuticals Inc - Frederick E. Pierce To Serve As Chief Executive Officer - Filing
Salarius jumps after completing merger with Decoy Therapeutics
Brief: Salarius Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Salarius Pharmaceuticals Inc Files For Mixed Shelf Of Up To $50 Million
Brief: Salarius Pharmaceuticals Announces 1-For-15 Reverse Stock Split
Brief: Salarius Pharmaceuticals Enters Second Amendment To Merger Agreement With Decoy - SEC Filing
Brief: Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces Its Novel Inhibitors Show Promising In Silico Activity Against Measles And Related Viruses
Brief: Salarius Pharmaceuticals And Decoy Therapeutics Announce Definitive Merger Agreement
Brief: Salarius Pharmaceuticals Enters Securities Purchase Agreement
Salarius Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Salarius Pharma falls on ending early-stage bone cancer study
Brief: Salarius Pharmaceuticals Says Now Determined To Close Ongoing Phase 1/2 Clinical Trial Evaluating Seclidemstat For Ewing Sarcoma